Renal cell carcinoma: molecular pathways and targeted therapy

被引：0

作者：

Gnjidic, Milena ^{[1
]}

Fucak, Iva Kardum ^{[2
]}

机构：

[1] Univ Hosp Ctr Zagreb, Dept Med Oncol, Div Oncol, Zagreb 10000, Croatia

[2] Gen Hosp Dr T Bardek, Dept Internal Med, Koprivnica, Croatia

来源：

PERIODICUM BIOLOGORUM | 2014年 / 116卷 / 04期

关键词：

renal cell carcinoma; molecular pathways; targeted therapy; TUMOR-SUPPRESSOR PROTEIN; CANCER; BIOLOGY; BINDING; MANAGEMENT; HIF1-ALPHA;

D O I：

暂无

中图分类号：

Q [生物科学];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Renal cell carcinoma (RCC) is not a single disease. A number of different types of cancer occur in the kidney and each is caused by different genes with different histology and clinical course. Studies of hereditary kidney cancer sydromes have led to identification of the main kidney cancer genes: VHL, MET, FH, SDH, FLCN, TSC1 and TSC2. Mutations in each of these genes lead to dysregulation of at least one metabolic pathway that is mediated by oxygen, iron, energy and nutrient sensing suggesting that renal cell cancer is a disease of dysregulated cellular metabolism. A more improved understanding of molecular pathways has led to development of targeted therapies. Targeted agents against VEGF, VEGFR and mTOR continue to play a crucial role in the management of metastatic RCC. However, complete response is extremely rare, resistance in tumor cells develops frequently and adverse effects of therapy are not unusual finding. For that reason further genetic and epigenetic changes, metabolic aberrations as well as immune response are beeing investigated in numerous studies to find new targets for more personalized therapy.

引用

页码：393 / 398

页数：6

共 33 条

[1] Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling [J].

Baba, Masaya ;

Hong, Seung-Beom ;

Sharma, Nirmala ;

Warren, Michelle B. ;

Nickerson, Michael L. ;

Iwamatsu, Akihiro ;

Esposito, Dominic ;

Gillette, William K. ;

Hopkins, Ralph F., III ;

Hartley, James L. ;

Furihata, Mutsuo ;

Oishi, Shinya ;

Zhen, Wei ;

Burke, Terrence R., Jr. ;

Linehan, W. Marston ;

Schmidt, Laura S. ;

Zbar, Berton .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (42) :15552-15557

[2] mTOR Pathway and mTOR Inhibitors as Agents for Cancer Therapy [J].

Baldo, Paolo ;

Cecco, Sara ;

Giacomin, Elisa ;

Lazzarini, Renzo ;

Rose, Barbara ;

Marastoni, Stefano .

CURRENT CANCER DRUG TARGETS, 2008, 8 (08) :647-665

[3]

Bjornsson J, 1996, AM J PATHOL, V149, P1201

[4] Molecular Genetics of Clear-Cell Renal Cell Carcinoma [J].

Brugarolas, James .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (18) :1968-+

[5] The tuberous sclerosis complex [J].

Crino, Peter B. ;

Nathanson, Katherine L. ;

Henske, Elizabeth Petri .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (13) :1345-1356

[6] Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J].

Escudier, B. ;

Porta, C. ;

Schmidinger, M. ;

Algaba, F. ;

Patard, J. J. ;

Khoo, V. ;

Eisen, T. ;

Horwich, A. .

ANNALS OF ONCOLOGY, 2014, 25 :49-56

[7] Tumor Biology and Prognostic Factors in Renal Cell Carcinoma [J].

Finley, David S. ;

Pantuck, Allan J. ;

Belldegrun, Arie S. .

ONCOLOGIST, 2011, 16 :4-13

[8] Negative regulation of hypoxia-inducible genes by the von Hippel Lindau protein [J].

Iliopoulos, O ;

Levy, AP ;

Jiang, C ;

Kaelin, WG ;

Goldberg, MA .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (20) :10595-10599

[9] Molecular biology of renal cell cancer and the identification of therapeutic targets [J].

Iliopoulos, Othon .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (35) :5593-5600

[10] Potential Role of Genetic Markers in the Management of Kidney Cancer [J].

Junker, Kerstin ;

Ficarra, Vincenzo ;

Kwon, Eugene D. ;

Leibovich, Bradley C. ;

Thompson, R. Houston ;

Oosterwijk, Egbert .

EUROPEAN UROLOGY, 2013, 63 (02) :333-340

← 1 2 3 4 →